Beyond Affordability: The Bioethics of Inclusion and Justice in Advanced Therapies

The article by Ogbogu and Albrecht, “Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches” [1], offers an insightful dual framework—rehabilitative and transformative—for confronting the affordability crisis surrounding advanced therapies. Their discussion elegantly captures the structural and market dynamics that impede equitable distribution. Yet, from a bioethical standpoint, two closely related dimensions merit deeper consideration: the ethics of inclusion in global research and the moral responsibility toward intergenerational equity in low- and middle-income countries (LMICs). First, access is not merely an economic problem but a question of moral participation. The transformative paradigm described by the authors presupposes that local innovation ecosystems in LMICs can be mobilized through technology transfer and adaptive regulation. However, the historical pattern of biomedical development reveals a deeper asymmetry: populations in the Global South frequently serve as sites of data collection, biological sampling, or post-market surveillance without equitable ownership of resulting technologies [2]. Bioethically, this exclusion challenges the principles of justice and respect for communities that contribute to the knowledge base enabling such therapies. Ensuring genuine inclusion requires not only local production capacity but also fair authorship, shared intellectual property, and decision-making power in trial design and priority-setting. Otherwise, “transformative” reforms risk replicating dependency under a new rhetoric of accessibility. Second, affordability discussions rarely address the intergenerational dimensions of justice. Advanced therapies—by design, often curative and long-acting—hold profound implications for future health resource allocation. In many LMICs, introducing such therapies for rare diseases could divert funds from essential public health programs, thereby privileging a few present beneficiaries at the expense of population-wide preventive care [3]. Ethically, the question is not simply whether an intervention can be made affordable, but whether its adoption aligns with distributive priorities that safeguard the health of future generations. Cost-sharing models and value-based pricing, as the authors discuss, are economically innovative but ethically incomplete unless accompanied by frameworks that ensure sustainable solidarity across generations and socioeconomic strata. A further challenge lies in the governance of cross-border collaborations. The authors rightly emphasize intellectual property reform and adaptive regulation, yet these strategies must also confront the risk of “bioeconomic extraction,” where the promise of capacity-building conceals inequitable benefit flows. From a global bioethics perspective, this requires transparent governance mechanisms—independent ethics review bodies with international representation, equitable licensing clauses for LMIC manufacturers, and community-level benefit-sharing agreements. Only then can the transformative agenda genuinely reflect the reciprocity and justice that define ethical innovation. In essence, affordability and access are necessary but not sufficient conditions for ethical legitimacy. As gene and cell therapies advance, bioethics must expand its focus beyond cost-effectiveness and inclusion metrics to interrogate who participates in, benefits from, and bears the opportunity costs of this technological frontier. Integrating distributive and intergenerational ethics into the authors' framework would ensure that “making therapies accessible” does not merely redistribute products, but redefines the moral architecture of global health innovation. The authors have nothing to report. The authors declare no conflicts of interest.